Company Overview and News


Add IPH
to your dashboard

Headline News

3 Things In Biotech You Should Learn Today: November 27, 2017

2017-11-27 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Innate Pharma's (IPHYF) CEO Mondher Mahjoubi on Q2 2017 Results - Earnings Call Transcript

2017-09-18 seekingalpha
Good afternoon ladies and gentlemen, and welcome to the Innate Pharma Healthcare 2017 Results Conference Call. At this time all participants are in listen-only mode. Later we will conduct the question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. (72-0)

Dragonfly Therapeutics nombra director científico a un líder mundial en inmunoterapias

2017-06-27 prnewswire
- Dragonfly Therapeutics nombra director científico al líder mundial en tratamientos basados en linfocitos citolíticos naturales

Dragonfly Therapeutics macht weltweit führenden NK-Zelltherapie-Experten zum Chief Scientific Officer

2017-06-26 prnewswire
Dr. Wagtmann, Ph.D, ein weltweit anerkannter Wissenschaftler mit mehr als 20 Jahren Erfahrung im Bereich Biotech und Pharma, tritt dem Dragonfly-Team bei, um die Weiterentwicklung von neuartigen auf natürlichen Killerzellen (NK) beruhenden Immuntherapien zu unterstützen.

New Dogs For Old Tricks

2017-06-16 seekingalpha
Away from the limelight of the Juliet study of Novartis' (NYSE:NVS) CAR-T lead, CTL019, this week's International Conference on Malignant Lymphoma played host to several novel approaches targeting tried and tested pharmacological pathways.

Innate Pharma to Develop Novo Nordisk's Anti-C5aR Antibody for Cancer

2017-06-05 genengnews
Cancer antibody therapeutics firm Innate Pharma is paying Novo Nordisk €40 million (approximately $45 million) upfront for global rights to develop and commercialize the latter’s anti-C5aR antibody (designated IPH5401). Novo Nordisk has previously carried out two Phase I studies with the antibody in patients with rheumatoid arthritis, but Innate says the antibody will represent a new therapeutic approach for immuno-oncology indications.

Array BioPharma And Columbus's Egg - Array BioPharma Inc. (NASDAQ:ARRY) | Seeking Alpha

2017-04-04 seekingalpha
First approval is very likely, and it will thus play a strategic role as a forerunner, waiting for bigger opportunity.

Array BioPharma And Columbus's Egg

2017-03-15 seekingalpha
First approval is very likely, and it will thus play a strategic role as a forerunner, waiting for bigger opportunity.

Innate Pharma 2016 Q4 - Results - Earnings Call Slides

2017-03-07 seekingalpha
The following slide deck was published by Innate Pharma in conjunction with their 2016 Q4 earnings call.

Innate Pharma's (IPHYF) CEO Mondher Mahjoubi on Q4 2016 Results - Earnings Call Transcript

2017-03-07 seekingalpha
Ladies and gentlemen, welcome to the Innate Pharma Conference Call. I’ll now hand over to Mondher Mahjoubi, CEO. Sir, please go ahead.

Bristol-Myers Squibb And Innate Pharma: Innovation Is Never A Single Event

2017-03-06 seekingalpha
Cash, cash equivalents and financial assets of Innate Pharma were €239M at the end of 3Q16.

AACR - Rags To Riches To Rags Again

2017-03-03 seekingalpha
Yesterday’s unveiling of many of the abstracts for the upcoming annual meeting of the American Association for Cancer Research produced two immediate winners – Karyopharm (NASDAQ:KPTI) and Newlink Genetics (NASDAQ:NLNK). But the dust had not even settled before the former slumped on a clinical setback for its lead asset, selinexor.

Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial

2017-02-06 genengnews
Imagine the U.S. Population in Microcosm, With All of Its Diversity Represented by Tissue Samples from More Than 1 Million Participants

Another Letdown for Bristol-Myers Squibb as Partner Innate Pharma's Leukemia Candidate Flunks Phase II Test

2017-02-06 biospace
Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia